Peter Revill

Viperin binds STING and enhances the type-I interferon response following dsDNA detection

Keaton M Crosse, Ebony A Monson, Arti B Dumbrepatil, Monique Smith, Yeu-Yang Tseng, Kylie H Van der Hoek, Peter A Revill, Subir Saker, David C Tscharke, E Neil G Marsh, Michael R Beard, Karla J Helbig

Journal article  |  2020  |  Immunology and Cell Biology

HBV-STOP study: Large hepatitis B virus flares off nucleot(s)ide analog therapy cause large innate immune response

S Hall, G Burns, D Anagnostou, R Morris, B Mooney, M Levy, W Sievert, J Lubel, A Nicoll, S Strasser, P Desmond, M Ngu, P Angus, C Meredith, P Revill, K Jackson, S Bowden, S Locarnini, A Thompson, K Visvanathan

Conference Proceedings  |  2020  |  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

FUNCTIONAL CURE OF CHRONIC HEPATITIS B IS ASSOCIATED WITH CO-OCCURRENCE OF HBsAg/ANTI-HBS IMMUNE COMPLEXES WITH ALT FLARES, AND SEROCONVERSION TO NEUTRALISING ANTI-HBS

Hui Xu, Stephen Locarnini, Darren Wong, Renae Walsh, Sally Soppe, Danni Coledge, Rachel Hammond, Alexander Thompson, Peter Revill, Patrick Marcellin, Anuj Gagger, Nadia Warner

Conference Proceedings  |  2020  |  HEPATOLOGY

A prospective study of nucleot(s)ide analog discontinuation in non-cirrhotic patients with HBeAg-negative chronic hepatitis B: Interim analysis identifies different viral kinetics after stopping tenofovir versus entecavir

S Hall, G Burns, D Anagnostou, S Vogrin, M Levy, W Sievert, J Lubel, A Nicoll, S Strasser, P Desmond, M Ngu, P Angus, C Meredith, P Revill, K Jackson, S Bowden, S Locarnini, K Visvanathan, A Thompson

Conference Proceedings  |  2020  |  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

HEPATITIS B VIRUS GENOTYPES EXHIBIT DIFFERENT INFECTIVITY, VIROLOGICAL FEATURES AND IFN-A RESPONSES IN CELL CULTURE AND ANIMAL MODELS

Min Zhang, Zhensheng Zhang, Michio Imamura, Mitsutaka Osawa, Yuji Teraoka, Jason Piotrowski, Yuji Ishida, Peter Revill, Takeshi Saito, Kazuaki Chayama, T Jake Liang

Conference Proceedings  |  2020  |  HEPATOLOGY

Analysis of Hepatitis B virus haplotype diversity detects striking sequence conservation across genotypes and chronic disease phase.

Josef Wagner, Lilly Yuen, Margaret Littlejohn, Vitina Sozzi, Kathy Jackson, Vithika Suri, Susanna Tan, Becket Feierbach, Anuj Gaggar, Patrick Marcellin, Maria Buti Ferret, Harry LA Janssen, Ed Gane, Henry LY Chan, Danni Colledge, Gillian Rosenberg, Julianne Bayliss, Benjamin P Howden, Stephen A Locarnini, Darren Wong, et al.

Journal article  |  2020  |  Hepatology

BACKGROUND: We conducted haplotype analysis of complete hepatitis B virus (HBV) genomes following deep sequencing from 368 patient..

HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B

Lilly Yuen, Peter A Revill, Gillian Rosenberg, Josef Wagner, Margaret Littlejohn, Julianne Bayliss, Kathy Jackson, Susanna K Tan, Anuj Gaggar, Kathryn Kitrinos, Mani Subramanian, Ed Gane, Henry LY Chan, Xin Li, Scott Bowden, Stephen Locarnini, Alexander Thompson

Journal article  |  2020  |  Journal of Viral Hepatitis

Nucleos(t)ide analouges (NUC) treatment prevents progression of liver fibrosis in subjects with chronic hepatitis B (CHB). However..

The evolution and clinical impact of hepatitis B virus genome diversity

Peter A Revill, Thomas Tu, Hans J Netter, Lilly KW Yuen, Stephen A Locarnini, Margaret Littlejohn

Journal article  |  2020  |  Nature Reviews Gastroenterology & Hepatology

The global burden of hepatitis B virus (HBV) is enormous, with 257 million persons chronically infected, resulting in more than 88..

Editorial: Strategies and barriers for hepatitis B cure: implications for HIV

Peter A Revill, Sharon R Lewin

Journal article  |  2020  |  Current Opinion in HIV and AIDS

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡.

Markus Cornberg, Anna Suk-Fong Lok, Norah A Terrault, Fabien Zoulim, undefined 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty

Journal article  |  2020  |  Journal of Hepatology

Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of d..